AU Patent

AU2004259741A1 — (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt and anhydrous crystalline forms thereof

Assigned to SmithKline Beecham Corp · Expires 2005-02-03 · 21y expired

What this patent protects

The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.

USPTO Abstract

The present invention includes anhydrous crystalline forms of (2S,4S)-4-fluoro-1-[4-fluoro-beta-(4-fluorophenyl)-L-phenylalanyl]-2-pyrrolidinecarbonitrile p-toluenesulfonic acid salt.

Drugs covered by this patent

Patent Metadata

Patent number
AU2004259741A1
Jurisdiction
AU
Classification
—
Expires
2005-02-03
Drug substance claim
No
Drug product claim
No
Assignee
SmithKline Beecham Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.